AZN Latest Press Releases

-- May 28, 2026 --

IMFINZI (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-nave, high-risk non-muscle-invasive bladder cancer Business Wire 9:18 PM

-- May 22, 2026 --

DATROWAY (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates Business Wire 10:16 AM

Datroway Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates Business Wire 9:30 AM

Enhertu Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors Business Wire 8:00 AM

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 Business Wire 7:00 AM

-- May 18, 2026 --

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension Business Wire 7:00 AM

-- May 15, 2026 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer Business Wire 9:52 PM

Enhertu Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer Business Wire 6:31 PM

-- May 14, 2026 --

Perioperative IMFINZI (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial Business Wire 7:00 AM

-- April 30, 2026 --

TRUQAP (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer Business Wire 9:42 PM

-- April 29, 2026 --

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca PRNewswire 7:00 PM

AstraZeneca results: Q1 2026 Business Wire 7:00 AM

-- April 28, 2026 --

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older Business Wire 7:00 AM

-- April 27, 2026 --

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus Business Wire 7:00 AM

-- April 20, 2026 --

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD Business Wire 7:00 AM

-- April 2, 2026 --

IMFINZI (durvalumab) + IMJUDO (tremelimumab-actl) improves PFS in early liver cancer Business Wire 7:00 AM

-- March 27, 2026 --

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD Business Wire 7:00 AM

-- March 10, 2026 --

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer Business Wire 8:30 AM

-- March 9, 2026 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer Business Wire 7:00 AM

ENHERTU Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer Business Wire 2:30 AM

-- February 20, 2026 --

CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting Business Wire 7:00 AM

-- February 19, 2026 --

ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer Business Wire 2:30 AM

-- February 13, 2026 --

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine Business Wire 7:00 AM

-- February 11, 2026 --

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US Business Wire 9:00 AM

-- February 10, 2026 --

AstraZeneca results: FY and Q4 2025 Business Wire 7:00 AM

-- February 3, 2026 --

DATROWAY (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Business Wire 7:00 AM

DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy Business Wire 2:30 AM

-- February 2, 2026 --

AstraZeneca begins trading on the New York Stock Exchange Business Wire 7:00 AM

-- January 19, 2026 --

ENHERTU Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer Business Wire 2:30 AM

-- January 13, 2026 --

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer Business Wire 7:00 AM

-- January 9, 2026 --

Walmart Inc. to Join the Nasdaq-100 Index Beginning January 20th, 2026 Globe Newswire 8:00 PM

-- January 8, 2026 --

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit Business Wire 7:00 AM